Policy Comments
The priority legislative and regulatory issues that the Cancer Policy Institute focuses on are driven by policy pillars that are centered around the values, needs, and preferences of individuals impacted by cancer. We work in conjunction with patients, patient advocacy organizations, medical associations, and other stakeholders to advance policies aimed at improving access to, affordability of, and quality of care across the cancer continuum.
Group letter to CMS commenting on the CY 2025 MPFS Proposed Rule regarding caregiver training services
Group letter commenting on the FY2025 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems (OPPS) proposed rule, with the goal of increasing access to safe CAR T therapy in outpatient settings
Organization sign-on letter to Congressional leadership, urging them to prioritize a patient-centered approach when considering and advancing health care legislation to ensure that patient, survivor, and caregiver perspectives are incorporated in conversations about policies that stand to impact them the most.
Group letter to House and Senate leadership urging the passage of a meaningful PBM reform package that ensures transparency and accountability for PBMs and their practices, and prioritizes the needs of patients
Group letter supporting the Consumer Financial Protection Bureau's (CFPB) proposed rule on medical debt reporting.
Group letter supporting the passage of the Cancer Drug Parity Act (HR 6301/S. 2039) and the inclusion of this policy in any reforms to the 21st Century Cures Act
Group letter re supporting the rule’s prohibiting of creditors using medical debt information and status form making credit determinations
Group letter endorsing the Radiation Oncology Case Rate Value-Based Payment Program Act of 2024 with the goal of moving towards a cancer care system that reimburses for quality and value of care rather than paying per treatment.
Group letter to CMS related to their recent guidance for implementing the Medicare Drug Negotiation Program. Comments focus on agency's process for engaging patients in its decisions, including determinations related to a treatment’s clinical effectiveness, unmet need and therapeutic alternatives, as well as the agency’s use of value assessments.
Group letter to CMS providing comments on the draft guidance of the Medicare Drug Price Negotiation Program (MDPNP) for 2027.